Clinical Trial

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

Study acronym: COVE-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2026-01-19
Trial Details
NCT Number NCT07246590
Lead Sponsor Verrica Pharmaceuticals Inc.
Collaborators: Canfield Scientific Inc., Medidata Solutions, Veeva Systems, Torii Pharmaceutical Co. Ltd., Allucent (US) LLC, Myonex LLC
Conditions Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Enrollment 300 participants
Start Date 2025-12-17
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-21